Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
ArticleFull Access

Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study

Published Online:1 Feb 2003https://doi.org/10.1176/appi.ajp.160.2.297

References

  • 1. Perkins DO: Adherence to antipsychotic medications. J Clin Psychiatry 1999; 60(suppl 21):25-30 Google Scholar
  • 2. Blackburn GL: Weight gain and antipsychotic medication. J Clin Psychiatry 2000; 61(suppl 8):36-42 Google Scholar
  • 3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696 Abstract, Google Scholar
  • 4. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358-363 Crossref, Medline, Google Scholar
  • 5. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100 Crossref, Medline, Google Scholar
  • 6. Lund BC, Perry PJ, Brooks JM, Arndt S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch Gen Psychiatry 2001; 58:1172-1176 Crossref, Medline, Google Scholar
  • 7. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL: Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(suppl 23):45-66 Google Scholar
  • 8. Campfield LA, Smith FJ, Burn P: Strategies and potential molecular targets for obesity treatment. Science 1998; 280:1383-1387 Crossref, Medline, Google Scholar
  • 9. Bymaster F, Perry KW, Nelson DL: Olanzapine: a basic science update. Br J Psychiatry 1999; 37(suppl):36-40 Google Scholar
  • 10. Schutz G, Berk M: Reboxetine add-on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001; 16:275-279 Crossref, Medline, Google Scholar
  • 11. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995 Google Scholar
  • 12. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1983 Google Scholar
  • 13. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983 Google Scholar
  • 14. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222 Google Scholar
  • 15. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62 Crossref, Medline, Google Scholar
  • 16. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676 Crossref, Medline, Google Scholar
  • 17. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19 Crossref, Medline, Google Scholar
  • 18. Kanders BS, Forse RA, Blackburn GL: Methods in obesity, in Conn’s Current Therapy. Edited by Rakel RE. Philadelphia, WB Saunders, 1991, pp 524-532 Google Scholar
  • 19. Wetterling T, Mubigbrodt H: Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19:316-321 Crossref, Medline, Google Scholar
  • 20. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A: Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159:1058-1060 Link, Google Scholar
  • 21. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ: Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997; 121:1758-1762 Crossref, Medline, Google Scholar
  • 22. Tatsumi M, Jansen K, Blakely RD, Richelson E: Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368:277-283 Crossref, Medline, Google Scholar
  • 23. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159:1055-1057 Link, Google Scholar
  • 24. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37:177-193 Crossref, Medline, Google Scholar
  • 25. Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000; 39:413-427 Crossref, Medline, Google Scholar
  • 26. Aronne LJ: Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001; 62(suppl 23):13-22 Google Scholar